First results on TIM-3 antibody monotherapy in a phase I trial in advanced solid cancers showed only little response.289In advanced MSI-H/dMMR tumors (phase Ib), monotherapy as well as combination with anti-PD-(L)1 showed surprisingly high response rates up to 45%.290Of note, responses were always more favorable if patients initially responded to anti-PD-(L)1 therapy, highlighting the potential use of alternative ICI therapy in acquired ICI resistance.225In primary liver cancer, combination of anti-TIM3 with anti-PD1 is currently under investigation (NCT03680508). The gene discussed is CD274; the disease is liver cancer.